Zno@Pda@Ag Nanocomposite-Mediated Delivery Of 9-Bromonoscapine, An Anticancer Agent, For Enhanced Lung Cancer Therapy

The study presents a biocompatible nanocomposite, ZnO@PDA@Ag@9-Br-Nos, designed for enhanced lung cancer therapy. This nanocomposite, which incorporates the hydrophobic anticancer drug 9-bromonoscapine, demonstrated efficient drug loading (69.4%) and sustained release at physiological pH. Characterization confirmed its stability and functional integrity. In vitro tests showed significant cytotoxicity against H1299 lung cancer cells with an IC50 of 33.51±4.54 µg/mL, while maintaining non-toxicity to normal cells and human erythrocytes. These results suggest that ZnO@PDA@Ag@9-Br-Nos is a promising nanocarrier for targeted cancer treatment, warranting further investigation for translational applications.